Decaminju

Adult dosage

For adults, the maximum dosage is 1 to 1.5 g of total amino acids per kg of body weight administered via intravenous infusion. An infusion rate of approximately 10 g of total amino acids over 60 minutes is preferred, with a general guideline of 30 to 40 drops per minute.

Children's dosage

In children, the dosage and infusion rate should be adjusted appropriately.

This medication must be used according to a doctor's instructions. It should not be used in patients with hepatic coma or those at risk of hepatic coma. Patients with severe renal dysfunction or high blood nitrogen levels should not be administered this drug. It is also advisable to avoid administering this medication to patients with nitrogen metabolism issues. Patients with severe heart failure, pulmonary edema, very low or absent urine output, and those with acidosis should avoid using this medication. Patients with excessive body fluid or low blood potassium levels should also not be administered this drug. Patients in shock or with a history of myocardial infarction should not use this drug. Care should be taken when administering this drug to patients with congestive heart failure or liver or renal dysfunction. Rarely, hypersensitivity reactions such as skin rashes may occur with this drug, and administration should be stopped immediately if such symptoms appear. Occasionally, gastrointestinal symptoms such as nausea or vomiting may arise. Cardiac-related symptoms may include chest discomfort, palpitations, rapid heartbeat, and elevated blood pressure. Rapid administration of large doses of this medication may result in metabolic acidosis. Shivers, fever, headache, respiratory distress or cessation, shock, bronchospasm, and urinary cramps may rarely occur. Complications such as metabolic acidosis, hypophosphatemia, alkalosis, elevated blood sugar, diabetes, dehydration, hypoglycemia, elevated liver enzymes, vitamin imbalances, electrolyte imbalances, and hyperammonemia in children may arise. Patients with poor liver or kidney function may have elevated blood urea nitrogen levels. Patients with severe liver dysfunction may experience severe symptoms such as amino acid imbalance, metabolic alkalosis, hyperammonemia, and coma. When administered in large amounts or in conjunction with electrolyte supplements, care must be taken with electrolyte balance. Overdosage may lead to metabolic alkalosis, hence preparations containing acidic ions should be used cautiously. Patients with a history of kidney disease, lung disease, or heart disease should be cautiously administered this medication to avoid excessive fluid accumulation in the body. Patients with diabetes should frequently monitor their blood sugar levels when using this medication. Some antibiotics may reduce the protein-preserving effect of this medication; caution is advised. The safety of this drug has not been established in pregnant women, and it should be used cautiously only if the therapeutic effect outweighs the risks. When administered to children, it is advisable to maintain a low concentration, and especially in neonates, there is a risk of hyperammonemia, so frequent monitoring of blood ammonia levels is necessary. Elderly patients may have reduced physical function, so it is important to administer at a slower rate and reduce the dose.</s> This drug should be administered slowly intravenously, and rapid infusion may cause chills or vomiting and can increase the excretion of amino acids through the kidneys. In cold seasons, it is advisable to warm the medication to body temperature for use. To prevent infection during administration, strict aseptic conditions should be maintained, and syringe equipment should be kept clean. If the solution is cloudy or discolored, it should not be used, and after mixing with other solutions, it should be used immediately and stored refrigerated for no more than 24 hours. If crystals develop, they should be gently melted and cooled to body temperature before use. When storing the drug, the packaging should not be opened, and if the container or packaging is damaged or discolored, it should not be used. Care should be taken to prevent leakage during use, and measurements should be made accurately according to the graduations on the container.

Serious side effects

• Chest tightness
• difficulty breathing
• respiratory arrest
• shock
• bronchospasm
• liver failure
• kidney failure
• loss of consciousness
• coma.

Mild side effects

Rarely, rash, nausea, vomiting, chest discomfort, palpitations, tachycardia, elevated blood pressure, metabolic acidosis upon rapid large doses, chills, fever, headache, urinary cramping, metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, osmotic diuresis and dehydration, reactive hypoglycemia, elevated liver enzymes, vitamin deficiency and excess, electrolyte imbalance, hyperammonemia in children, serum amino acid imbalance, metabolic alkalosis, and systemic nitrogen blood.

This medication should be stored in a sealed container to prevent air or moisture from entering, away from direct sunlight, and at room temperature. Proper storage will help maintain the effectiveness of the medication for a longer time.

Appearance

A clear solution that is colorless to pale yellow, filled in a colorless transparent glass container or polypropylene container as a parenteral preparation.

Package unit

250mL/bottle